WO2008132176A3 - Method for evaluating the response of an individual to tnf blocking therapy - Google Patents

Method for evaluating the response of an individual to tnf blocking therapy Download PDF

Info

Publication number
WO2008132176A3
WO2008132176A3 PCT/EP2008/055096 EP2008055096W WO2008132176A3 WO 2008132176 A3 WO2008132176 A3 WO 2008132176A3 EP 2008055096 W EP2008055096 W EP 2008055096W WO 2008132176 A3 WO2008132176 A3 WO 2008132176A3
Authority
WO
WIPO (PCT)
Prior art keywords
response
genes
tnf blocking
evaluating
individual
Prior art date
Application number
PCT/EP2008/055096
Other languages
French (fr)
Other versions
WO2008132176A2 (en
Inventor
Bernard Lauwerys
Valerie Badot
Frederic Houssiau
Den Eynde Benoit Van
Original Assignee
Univ Catholique Louvain
Cliniques Universitaires Saint
Bernard Lauwerys
Valerie Badot
Frederic Houssiau
Den Eynde Benoit Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Catholique Louvain, Cliniques Universitaires Saint, Bernard Lauwerys, Valerie Badot, Frederic Houssiau, Den Eynde Benoit Van filed Critical Univ Catholique Louvain
Publication of WO2008132176A2 publication Critical patent/WO2008132176A2/en
Publication of WO2008132176A3 publication Critical patent/WO2008132176A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is directed to methods to predict the responsiveness of a patient to a TNF blocking drug comprising the steps of: a) assessing in a synovial sample from said patient at least two genes or a fragment thereofs or proteins encoded by said at least two genes, wherein said genes or fragment thereof is as defined in claim 1, and b) predicting the response to the treatment with the TNF blocking agent in said patient by evaluating the results of step (a). The invention is also directed to kits for predicting the response to a treatment with a TNF blocking agent comprising a low density microarray comprising probes suitable for hybridizing with at least two genes or fragments thereof as defined in the claims.
PCT/EP2008/055096 2007-04-27 2008-04-25 Method for evaluating the response of an individual to tnf blocking therapy WO2008132176A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07107087 2007-04-27
EP07107087.4 2007-04-27

Publications (2)

Publication Number Publication Date
WO2008132176A2 WO2008132176A2 (en) 2008-11-06
WO2008132176A3 true WO2008132176A3 (en) 2009-04-09

Family

ID=38442071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/055096 WO2008132176A2 (en) 2007-04-27 2008-04-25 Method for evaluating the response of an individual to tnf blocking therapy

Country Status (1)

Country Link
WO (1) WO2008132176A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5719591B2 (en) * 2007-06-08 2015-05-20 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． Biomarker for predicting anti-TNF responsiveness or non-responsiveness
ES2335381B1 (en) * 2008-09-24 2011-02-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron IN VITRO METHOD AND KIT FOR THE FORECAST OR PREDICTION OF THE RESPONSE PART OF PATIENTS WITH REUMATOID ARTHRITIS TO THE TREATMENT WITH BLOCKING AGENTS OF THE TNFALFA FACTOR.
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2011085811A1 (en) * 2010-01-14 2011-07-21 Universite Catholique De Louvain Method for evaluating the response of rheumatoid arthritis patients to therapy and for diagnosing disease severity
US20120088681A1 (en) 2010-02-05 2012-04-12 The Translational Genomics Research Institute Methods and kits used in classifying adrenocortical carcinoma
RS61082B1 (en) 2010-02-26 2020-12-31 Novo Nordisk As Stable antibody containing compositions
JP2013526845A (en) * 2010-03-24 2013-06-27 ティーシー・ランド・エクスプレッション Genes and combinations of genes that predict an initial response or non-response of a subject suffering from an inflammatory disease to a cytokine targeted drug (CyTD)
RU2012153786A (en) 2010-05-28 2014-07-10 Ново Нордиск А/С STABLE MULTI-DOSE COMPOSITIONS CONTAINING ANTIBODY AND CONSERVANT
MY166040A (en) 2010-09-15 2018-05-21 Almac Diagnostics Ltd Molecular diagnostic test for cancer
GB201018147D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Method of treatment
WO2012061620A1 (en) * 2010-11-04 2012-05-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2012101183A2 (en) * 2011-01-25 2012-08-02 Tc Land Expression Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs
BR112013021725A2 (en) 2011-02-28 2016-11-01 Genentech Inc biological markers and methods for predicting response to b-cell antagonists
WO2013071247A1 (en) * 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene expression signatures of neoplasm responsiveness to theraphy
JP5676777B2 (en) * 2011-11-17 2015-02-25 株式会社Ｄｎａチップ研究所 Method for identifying rheumatoid arthritis activity index and biomarker used therefor
CA2864133A1 (en) 2012-02-10 2013-08-15 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2013135789A1 (en) * 2012-03-15 2013-09-19 Universiteit Hasselt Means and methods for the determination of the joint destruction progression rate in rheumatoid arthritis patients
HU230680B1 (en) * 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnostic method
EP2813850A1 (en) * 2013-06-10 2014-12-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting rheumatoid arthritis treatment response
WO2016015779A1 (en) * 2014-08-01 2016-02-04 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Method to predict the lack of response to anti-tnf alpha therapies
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
US10022397B2 (en) * 2016-06-20 2018-07-17 Nobilis Therapeutics, Inc. Treatment of rheumatoid arthritis using noble gas mixtures
US20240329032A1 (en) * 2021-07-21 2024-10-03 Aspen Neuroscience, Inc. Methods of differentiating neural cells and predicting engraftment thereof and related compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030154032A1 (en) * 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
WO2006122187A2 (en) * 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2007038501A2 (en) * 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030154032A1 (en) * 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
WO2006122187A2 (en) * 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2007038501A2 (en) * 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE AFFYMETRIX [online] 2003, "GeneChip® Human Genome Arrays", XP002499246, retrieved from HTTP://WWW.AFFYMETRIX.COM/SUPPORT/TECHNICAL/DATASHEETS/HUMAN_DATASHEET.PDF *
HAEUPL T ET AL: "GENE EXPRESSION PROFILING OF RHEUMATOID ARTHRITIS SYNOVIAL CELLS TREATED WITH ANTIRHEUMATIC DRUGS", JOURNAL OF BIOMOLECULAR SCREENING, LARCHMONT, NY, US, vol. 12, no. 3, 1 April 2007 (2007-04-01), pages 328 - 340, XP009083067, ISSN: 1087-0571 *
LEQUERRÉ THIERRY ET AL: "Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 4, 3 July 2006 (2006-07-03), pages R105, XP021020585, ISSN: 1478-6354 *
LINDBERG J ET AL K ET AL: "Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients", ARTHRITIS RESEARCH AND THERAPY 2006 GB, vol. 8, 2006, XP002499154, ISSN: 1478-6354 1478-6362 *
STOJAN B. AND HASLER F.: "Immunological findings in serum and synovial fluid in patients with rheumatoid arthritis", WIENER KLINISCHE WOCHENSCHRIFT, vol. 89, no. 21, 11 November 1977 (1977-11-11), pages 713 - 716, XP002449443 *
VAN ROON JAG ET AL: "Interleukin 7 stimulates tumour necrosis factor [alpha] and Th 1 cytokine production in joints of patients with rheumatoid arthritis", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, vol. 62, no. 2, 1 February 2003 (2003-02-01), pages 113 - 119, XP008101195, ISSN: 0003-4967 *
VAN ROON JOEL AG ET AL: "Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, vol. 66, no. 5, 21 December 2006 (2006-12-21), pages 664 - 669, XP008101194, ISSN: 0003-4967, [retrieved on 20061221] *

Also Published As

Publication number Publication date
WO2008132176A2 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2008132176A3 (en) Method for evaluating the response of an individual to tnf blocking therapy
Tzouvelekis et al. Epigenetics in idiopathic pulmonary fibrosis
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
WO2006085684A3 (en) Method of diagnosing bladder cancer
WO2008115419A3 (en) Gene expression markers for prediction of patient response to chemotherapy
WO2007092640A3 (en) Antibodies that bind par-2
WO2008140774A3 (en) Methods for diagnosing and treating prostate and lung cancer
JP2006506979A5 (en)
WO2009120341A3 (en) Biomarkers for predicting response to immunosuppressive therapy
WO2007073171A3 (en) Improved strategies for transcript profiling using high throughput sequencing technologies
WO2006036744A3 (en) Methods for a global assay of coagulation and fibrinolysis
WO2007122369A8 (en) Novel tumour suppressor
NZ620799A (en) Molecular diagnostic test for cancer
WO2008060651A8 (en) Sparc and methods of use thereof
WO2003083140A3 (en) Classification and prognosis prediction of acute lymphoblasstic leukemia by gene expression profiling
WO2005048823A3 (en) Modeling of systemic inflammatory response to infection
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2008089072A3 (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
WO2010037859A3 (en) Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2011133949A3 (en) Genetic risk analysis in reward deficiency syndrome
WO2006026074A3 (en) Atherosclerotic phenotype determinative genes and methods for using the same
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
WO2006135893A3 (en) Methods for diagnosing and treating cerebrovascular events based on nr2 peptides
EP1930446A3 (en) Method for obtaining information regarding quantity of DNA after non-methylated cytosine converting treatment in analysis of DNA methylation
WO2006116688A3 (en) Mif agonists and antagonists and therapeutic uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08736588

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08736588

Country of ref document: EP

Kind code of ref document: A2